Warp Sciences
US chemistry contract research organization that combines medicinal chemists, AI and lab robotics to make research compounds for biotech and pharma drug discovery teams.
Warp Sciences has raised $215M across 1 disclosed round since Oct 22, 2026; the latest round, Series A, was announced on Oct 22, 2026. Data as of Oct 23, 2026.
Headquartered in United States.
Latest from MEKAWIRE
Warp Sciences is a US chemistry contract research organization (CRO) for preclinical small-molecule drug programs. Its first service is analog synthesis during lead optimization at milligram to multi-gram scale, typically for molecules that need five to 15 synthetic steps, charged per compound delivered rather than per chemist. Experienced chemists run the work while the company automates more of it with AI and robotics and records every experiment, including failures, to train models. The company says it has no drug pipeline of its own. Co-founders are Kevin Weil (CEO, former OpenAI chief product officer and VP of science), Sol Reisberg (chief scientific officer, ex Terremoto Biosciences), DJ Patil (COO, former US chief data scientist) and Manohar Paluri (CTO, former VP at Meta Superintelligence Labs). It came out of stealth on Oct 22, 2026 with $215 million led by Lightspeed.
- Latest funding
- $215M
- Total funding
- $215M
- Latest valuation
- —
- Founded
- —
- Country
- United States
- Oct 22, 2026Series A$215M